|
1
|
Nakamura K, Ukawa S, Okada E, Hirata M,
Nagai A, Yamagata Z, Ninomiya T, Muto K, Kiyohara Y, Matsuda K, et
al: Characteristics and prognosis of Japanese male and female lung
cancer patients: The BioBank Japan Project. J Epidemiol.
27:S49–S57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Palma D, Visser O, Lagerwaard FJ,
Belderbos J, Slotman BJ and Senan S: Impact of introducing
stereotactic lung radiotherapy for elderly patients with stage I
non-small-cell lung cancer: A population-based time-trend analysis.
J Clin Oncol. 28:5153–5159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Timmerman R, Paulus R, Galvin J, Michalski
J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone
D, et al: Stereotactic body radiation therapy for inoperable early
stage lung cancer. JAMA. 303:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Onishi H, Shirato H, Nagata Y, Hiraoka M,
Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, et al:
Stereotactic body radiotherapy (SBRT) for operable stage I
non-small-cell lung cancer: Can SBRT be comparable to surgery? Int
J Radiat Oncol Biol Phys. 81:1352–1358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanai T, Endo M, Minohara S, Miyahara N,
Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka
T, et al: Biophysical characteristics of HIMAC clinical irradiation
system for heavy-ion radiation therapy. Int J Radiat Oncol Biol
Phys. 44:201–210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schulz-Ertner D and Tsujii H: Particle
radiation therapy using proton and heavier ion beams. J Clin Oncol.
25:953–964. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ando K and Kase Y: Biological
characteristics of carbon-ion therapy. Int J Radiat Biol.
85:715–728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyamoto T, Baba M, Sugane T, Nakajima M,
Yashiro T, Kagei K, Hirasawa N, Sugawara T, Yamamoto N, Koto M, et
al: Carbon ion radiotherapy for stage I non-small cell lung cancer
using a regimen of four fractions during 1 week. J Thorac Oncol.
2:916–926. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyamoto T, Baba M, Yamamoto N, Koto M,
Sugawara T, Yashiro T, Kadono K, Ezawa H, Tsujii H, Mizoe JE, et
al: Curative treatment of Stage I non-small-cell lung cancer with
carbon ion beams using a hypofractionated regimen. Int J Radiat
Oncol Biol Phys. 67:750–758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwata H, Murakami M, Demizu Y, Miyawaki D,
Terashima K, Niwa Y, Mima M, Akagi T, Hishikawa Y and Shibamoto Y:
High-dose proton therapy and carbon-ion therapy for stage I
non-small cell lung cancer. Cancer. 116:2476–2485. 2010.PubMed/NCBI
|
|
11
|
Shirai K, Nakagawa A, Abe T, Kawahara M,
Saitoh J, Ohno T and Nakano T: Use of FDG-PET in radiation
treatment planning for thoracic cancers. Int J Mol Imaging.
2012:6095452012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lardinois D, Weder W, Hany TF, Kamel EM,
Korom S, Seifert B, von Schulthess GK and Steinert HC: Staging of
non-small-cell lung cancer with integrated positron-emission
tomography and computed tomography. N Engl J Med. 348:2500–2507.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pieterman RM, van Putten JW, Meuzelaar JJ,
Mooyaart EL, Vaalburg W, Koëter GH, Fidler V, Pruim J and Groen HJ:
Preoperative staging of non-small-cell lung cancer with positron-
emission tomography. N Engl J Med. 343:254–261. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lammering G, de Ruysscher D, van Baardwijk
A, Baumert BG, Borger J, Lutgens L, van den Ende P, Ollers M and
Lambin P: The use of FDG-PET to target tumors by radiotherapy.
Strahlenther Onkol. 186:471–481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dooms C, Verbeken E, Stroobants S,
Nackaerts K, De Leyn P and Vansteenkiste J: Prognostic
stratification of stage IIIA-N2 non-small-cell lung cancer after
induction chemotherapy: A model based on the combination of
morphometric-pathologic response in mediastinal nodes and primary
tumor response on serial 18-fluoro-2-deoxy-glucose positron
emission tomography. J Clin Oncol. 26:1128–1134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mac Manus MP, Hicks RJ, Matthews JP, Wirth
A, Rischin D and Ball DL: Metabolic (FDG-PET) response after
radical radiotherapy/chemoradiotherapy for non-small cell lung
cancer correlates with patterns of failure. Lung Cancer. 49:95–108.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang W, Zhou T, Ma L, Sun H, Gong H, Wang
J, Yu J and Li B: Standard uptake value and metabolic tumor volume
of 18F-FDG PET/CT predict short-term outcome early in
the course of chemoradiotherapy in advanced non-small cell lung
cancer. Eur J Nucl Med Mol Imaging. 38:1628–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berghmans T, Dusart M, Paesmans M,
Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C,
Moreau M, Roelandts M, et al: Primary tumor standardized uptake
value (SUVmax) measured on fluorodeoxyglucose positron emission
tomography (FDG-PET) is of prognostic value for survival in
non-small cell lung cancer (NSCLC): A systematic review and
meta-analysis (MA) by the European Lung Cancer Working Party for
the IASLC Lung Cancer Staging Project. J Thorac Oncol. 3:6–12.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tashiro M, Ishii T, Koya J, Okada R,
Kurosawa Y, Arai K, Abe S, Ohashi Y, Shimada H, Yusa K, et al:
Technical approach to individualized respiratory-gated carbon-ion
therapy for mobile organs. Radiol Phys Technol. 6:356–366. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Cancer Institute, . Common
Terminology Criteria for Adverse Events (CTCAE v4.0). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmlNovember
14–2016
|
|
21
|
Coon D, Gokhale AS, Burton SA, Heron DE,
Ozhasoglu C and Christie N: Fractionated stereotactic body
radiation therapy in the treatment of primary, recurrent, and
metastatic lung tumors: The role of positron emission
tomography/computed tomography-based treatment planning. Clin Lung
Cancer. 9:217–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Burdick MJ, Stephans KL, Reddy CA, Djemil
T, Srinivas SM and Videtic GM: Maximum standardized uptake value
from staging FDG-PET/CT does not predict treatment outcome for
early-stage non-small-cell lung cancer treated with stereotactic
body radiotherapy. Int J Radiat Oncol Biol Phys. 78:1033–1039.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeda A, Yokosuka N, Ohashi T, Kunieda E,
Fujii H, Aoki Y, Sanuki N, Koike N and Ozawa Y: The maximum
standardized uptake value (SUVmax) on FDG-PET is a strong predictor
of local recurrence for localized non-small-cell lung cancer after
stereotactic body radiotherapy (SBRT). Radiother Oncol.
101:291–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang JY, Liu H, Balter P, Komaki R, Liao
Z, Welsh J, Mehran RJ, Roth JA and Swisher SG: Clinical outcome and
predictors of survival and pneumonitis after stereotactic ablative
radiotherapy for stage I non-small cell lung cancer. Radiat Oncol.
7:1522012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clarke K, Taremi M, Dahele M, Freeman M,
Fung S, Franks K, Bezjak A, Brade A, Cho J, Hope A, et al:
Stereotactic body radiotherapy (SBRT) for non-small cell lung
cancer (NSCLC): Is FDG-PET a predictor of outcome? Radiother Oncol.
104:62–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Na F, Wang J, Li C, Deng L, Xue J and Lu
Y: Primary tumor standardized uptake value measured on
F18-Fluorodeoxyglucose positron emission tomography is of
prediction value for survival and local control in non-small-cell
lung cancer receiving radiotherapy: Meta-analysis. J Thorac Oncol.
9:834–842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goodgame B, Pillot GA, Yang Z, Shriki J,
Meyers BF, Zoole J, Gao F, Dehdashti F, Patterson A, Siegel BA and
Govindan R: Prognostic value of preoperative positron emission
tomography in resected stage I non-small cell lung cancer. J Thorac
Oncol. 3:130–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nair VS, Krupitskaya Y and Gould MK:
Positron emission tomography 18F-fluorodeoxyglucose uptake and
prognosis in patients with surgically treated, stage I non-small
cell lung cancer: A systematic review. J Thorac Oncol. 4:1473–1479.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vesselle H, Schmidt RA, Pugsley JM, Li M,
Kohlmyer SG, Vallires E and Wood DE: Lung cancer proliferation
correlates with [F-18]fluorodeoxyglucose uptake by positron
emission tomography. Clin Cancer Res. 6:3837–3844. 2000.PubMed/NCBI
|
|
30
|
van Baardwijk A, Dooms C, van Suylen RJ,
Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S,
Stroobants S, Buell U, et al: The maximum uptake of
(18)F-deoxyglucose on positron emission tomography scan correlates
with survival, hypoxia inducible factor-1alpha and GLUT-1 in
non-small cell lung cancer. Eur J Cancer. 43:1392–1398. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Satoh Y, Onishi H, Nambu A and Araki T:
Volume-based parameters measured by using FDG PET/CT in patients
with stage I NSCLC treated with stereotactic body radiation
therapy: Prognostic value. Radiology. 270:275–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salavati A, Borofsky S, Boon-Keng TK,
Houshmand S, Khiewvan B, Saboury B, Codreanu I, Torigian DA, Zaidi
H and Alavi A: Application of partial volume effect correction and
4D PET in the quantification of FDG avid lung lesions. Mol Imaging
Biol. 17:140–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
